{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:20:01Z","timestamp":1783488001899,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1038\/s41574-021-00557-3","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T11:04:05Z","timestamp":1630494245000},"page":"643-644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Insights into immune checkpoint inhibitor-induced thyroiditis"],"prefix":"10.1038","volume":"17","author":[{"given":"Melissa G.","family":"Lechner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"557_CR1","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","volume":"6","author":"B Shankar","year":"2020","unstructured":"Shankar, B. et al. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol. 6, 1952\u20131956 (2020).","journal-title":"JAMA Oncol."},{"key":"557_CR2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab263","author":"CA Muir","year":"2021","unstructured":"Muir, C. A. et al. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J. Clin. Endocrinol. Metab. https:\/\/doi.org\/10.1210\/clinem\/dgab263 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"557_CR3","doi-asserted-by":"publisher","first-page":"eabb7495","DOI":"10.1126\/scitranslmed.abb7495","volume":"13","author":"Y Yasuda","year":"2021","unstructured":"Yasuda, Y. et al. CD4+ T cells are essential for the development of destructive thyroiditis induced by anti\u2013PD-1 antibody in thyroglobulin-immunized mice. Sci. Trans. Med. 13, eabb7495 (2021).","journal-title":"Sci. Trans. Med."},{"key":"557_CR4","doi-asserted-by":"publisher","first-page":"633032","DOI":"10.3389\/fonc.2021.633032","volume":"11","author":"Y Fan","year":"2021","unstructured":"Fan, Y. et al. Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis. Front. Oncol. 11, 633032 (2021).","journal-title":"Front. Oncol."},{"key":"557_CR5","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1158\/0008-5472.CAN-16-0194","volume":"76","author":"J Liu","year":"2016","unstructured":"Liu, J. et al. Assessing immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer. Cancer Res. 76, 5288\u20135301 (2016).","journal-title":"Cancer Res."},{"key":"557_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","volume":"569","author":"E Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz, E. et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569, 428\u2013432 (2019).","journal-title":"Nature"},{"key":"557_CR7","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1089\/thy.2016.0092","volume":"26","author":"R Sharma","year":"2016","unstructured":"Sharma, R., Di Dalmazi, G. & Caturegli, P. Exacerbation of autoimmune thyroiditis by CTLA-4 blockade: a role for IFN\u03b3-induced indoleamine 2, 3-dioxygenase. Thyroid 26, 1117\u20131124 (2016).","journal-title":"Thyroid"},{"key":"557_CR8","doi-asserted-by":"publisher","first-page":"102285","DOI":"10.1016\/j.jaut.2019.05.013","volume":"103","author":"D \u00c1lvarez-Sierra","year":"2019","unstructured":"\u00c1lvarez-Sierra, D. et al. Analysis of the PD-1\/PD-L1 axis in human autoimmune thyroid disease: insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J. Autoimmun. 103, 102285 (2019).","journal-title":"J. Autoimmun."},{"key":"557_CR9","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1089\/thy.2020.0075","volume":"30","author":"A Kotwal","year":"2020","unstructured":"Kotwal, A. et al. Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations. Thyroid 30, 1440\u20131450 (2020).","journal-title":"Thyroid"},{"key":"557_CR10","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1210\/en.2011-1356","volume":"152","author":"I Horie","year":"2011","unstructured":"Horie, I. et al. Induction of autoimmune thyroiditis by depletion of CD4+CD25+ regulatory T cells in thyroiditis-resistant IL-17, but not interferon-\u03b3 receptor, knockout nonobese diabetic-H2 h4 mice. Endocrinology 152, 4448\u20134454 (2011).","journal-title":"Endocrinology"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-021-00557-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-021-00557-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-021-00557-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T03:39:54Z","timestamp":1633837194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-021-00557-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["557"],"URL":"https:\/\/doi.org\/10.1038\/s41574-021-00557-3","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"1 September 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}